Approval of dolasetron expands antiemetic choices.
D000932:Antiemetics / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D017277:Drug Approval; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D011807:Quinolizines / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
D000932:Antiemetics; D000970:Antineoplastic Agents; D007211:Indoles; D011807:Quinolizines; C060344:dolasetron